全球扁平疣治疗市场 – 行业趋势及 2030 年预测

扁平部炎治疗市场分析及规模

睫状体平坦部炎的增加将成为导致市场增长扩大的主要驱动力。虽然睫状体平坦部炎通常是良性的，但在严重的情况下可能会导致严重的视力丧失。睫状体平坦部炎主要影响儿童和青少年。尽管患者因睫状体平坦部炎而失明的情况并不常见，但如果不及时治疗，多达 20% 的患者可能会遭受视力丧失。  

Data Bridge Market Research 分析，睫状体平坦部炎治疗市场规模将从 2022 年的 5951.1 亿美元增至 2030 年的 9998 亿美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 6.70%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

睫状体扁平苔藓治疗市场范围和细分

Market Definition

Pars planitis is when the eye's uvea, or center layer, becomes inflamed. In this condition, the restricted area (pars plana) between the colored section of the eye, called the iris, and the choroid becomes swelled. This can cause black, blurred vision, floating areas in the eyesight, and vision loss over time. Cataracts, macular edema, and retinal detachment may develop as the condition progresses.  

Global Pars Planitis Treatment Market Dynamics

Drivers

• Increasing Prevalence of Pars Planitis

The increasing incidence of pars planitis leads to the market's growth during the forecast period. Most cases of intermediate uveitis in children exist without an underlying disease. Its annual incidence has been reported to be 1.4 - 2 cases per 100,000 population in France and the United States (U.S.). Furthermore, in a retrospective study, Ozdal et al. witnessed pars planitis as the top cause of pediatric uveitis, with a rate of 24%. Thus, this increasing incidence of pars planitis leads to a higher demand for its treatment processes. This factor leads to the growth of the market.

• Increasing Treatment Variations in Pars Palnitis

There are increasing treatment options for pars planitis that lead to market growth. Treatment options include periocular corticosteroid (CS) injections followed by oral prednisone if considered ineffective, cryotherapy or laser photocoagulation, pars plana vitrectomy, and immunosuppressive treatment the market growth. Periocular CS injections are advantageous, mainly in unilateral or asymmetrical involvement patients and macular edema. Thus, this factor help in the market growth.

Opportunities

• Varied Availability of Diagnostic Procedures

There are varied diagnostic methods associated with this treatment that lead to the market's growth. The current four-step therapy consists of immunosuppressives, corticosteroids, anti-TNF-α agents, and pars plana vitrectomy or laser photocoagulation for managing complications. Few patients have severe disease in both eyes, and the best option is an oral agent that reduces the immune system. Therefore, this factor acts as a major factor that increases market growth.

Restraints/Challenges

• High Cost of Pars Planitis Treatment Methods

Various treatment processes are of high cost, which further impedes the market growth. Treatment methods such as cryotherapy or laser photocoagulation, and pars plana vitrectomy are very costly. They cannot be afforded by most of the hospitals in the underdeveloped and developing countries which starts affecting the patient's health. Thus, this factor impedes market growth.

This pars planitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pars planitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Pars Planitis Treatment Market Scope

The pars planitis treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Corticosteroid
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Surgery
• Cryotherapy
• Immunomodulatory Therapy
• Others

Diagnosis

• Blood Tests
• X-ray
• Magnetic Resonance Imaging (MRI)
• Others

Symptoms

• Blurred Vision
• Dark Floaters in the Visual Field
• Swelling Inside the Eye
• Vision Loss
• Glaucoma, Cataracts
• Retinal Detachment
• Others

Dosage

• Injection
• Tablets
• Eye Drops
• Others

Route of Administration

• Oral
• Intravenous
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

End User

• Clinic
• Hospital
• Others

Pars Planitis Treatment Market Regional Analysis/Insights

The pars planitis treatment market is analyzed and market size insights and trends are provided by treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel and end user as referenced above.

扁平部炎治疗市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于患者人数不断增加以及医疗保健领域的投资不断增加，预计亚太地区在预测期内将实现增长。此外，政府对治疗和诊断程序的支持不断增加也推动了市场增长。

由于主要市场参与者的存在和高可支配收入，北美在预测期内占据市场主导地位。此外，该地区发达的医疗保健基础设施将推动市场增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

扁平部炎治疗市场还为您提供每个国家/地区资本设备医疗支出增长、扁平部炎治疗市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对扁平部炎治疗市场的影响的详细市场分析。数据适用于 2011-2021 年的历史时期。

竞争格局和睫状体扁平苔藓治疗市场份额分析

睫状体扁平部炎治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对睫状体扁平部炎治疗市场的关注有关。

睫状体平坦部炎治疗市场的一些主要参与者包括：

• 量子低温技术公司（英国）
• BTG International Inc.（美国）
• CryoConcepts LP（美国）。
• Zimmer MedizinSysteme GmbH（德国）
• 美敦力（爱尔兰）
• Cortex 技术（丹麦）
• CooperSurgical, Inc.（美国）
•  AtriCure, Inc（美国）
•  Hologic, Inc.（美国）。
• 诺华公司（瑞士）
• 拜耳公司（德国）
• 礼来（美国）
• 默克公司（美国）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• AbbVie Inc.（美国）
• 太阳制药工业有限公司 (印度)
•  Aurobindo Pharma（印度）

SKU-67636